Paroxetine — Paxil — was once a major player in the SSRI market. Today, it occupies a much narrower clinical role. The reasons are worth knowing, because they teach you about side effect profiles, discontinuation syndromes, and pregnancy prescribing — three concepts that are easier to learn through paroxetine than any other SSRI.
- Class
- SSRI
- Mechanism
- SERT blockade; significant anticholinergic activity at therapeutic doses
- Typical dose
- 20-50 mg/day
- Half-life
- ~21 hours (shortest among SSRIs)
- FDA indications
- MDD, OCD, panic, PTSD, social anxiety, GAD, PMDD
- Key adverse effects
- Sexual dysfunction (highest among SSRIs), sedation, weight gain, anticholinergic effects (dry mouth, constipation, blurred vision, cognitive effects), substantial discontinuation syndrome
Black box: Suicidal thinking/behavior in pediatric and young adult patients
Largely supplanted by other SSRIs in modern practice due to side effect profile. Particularly avoid in pregnancy (cardiac risk), in older adults (anticholinergic burden), and in patients with adherence concerns (severe withdrawal syndrome).
Paroxetine blocks SERT, like all SSRIs. What makes it different is what else it blocks. Of the SSRIs, paroxetine is the most anticholinergic — it has meaningful muscarinic receptor blockade at therapeutic doses. That means dry mouth, constipation, blurred vision, urinary retention, and, in older patients, cognitive effects. Anticholinergic burden is one of the central drivers of "drug-induced dementia" in geriatric polypharmacy, and paroxetine is the SSRI that contributes most. In elderly patients, sertraline or escitalopram is almost always the better choice.
Paroxetine is the SSRI whose off-target properties — anticholinergic activity, potent 2D6 inhibition, and a short half-life — most shape its clinical character.
Mechanism note: Paroxetine's anticholinergic burden, discontinuation syndrome, and 2D6 inhibition make it a poor default — particularly in older adults — despite genuine efficacy.
The half-life is short — about twenty-one hours, the shortest of the SSRIs. Combined with high SERT affinity, the short half-life produces the most severe SSRI discontinuation syndrome of the class. Patients who miss two doses can experience flu-like symptoms, dizziness, paresthesias ("brain zaps"), mood changes, and a profound sense that something is wrong. Tapering paroxetine often takes weeks to months, and some patients require a fluoxetine bridge — switching to long-half-life fluoxetine before discontinuing — to get off it at all.
- Cost
- Generic: ~$5-15/month.
- Generic status
- Generic since 2003. Paxil CR brand still sometimes prescribed; mostly generic.
- Formulary typical
- Tier 1 generic. Some plans require PA for Paxil CR.
- Access friction
- Easy to get; harder to taper off. Severe discontinuation syndrome means patients often need bridging strategies or very slow tapers.
Prescriber tip: Rarely the right new prescription. If continuing established responders, fine. For taper, consider fluoxetine bridge for hardest cases. Avoid initiating in women of childbearing potential.
Sexual dysfunction is highest with paroxetine among the SSRIs, often above 50% at therapeutic doses. Weight gain is more prominent than with sertraline or escitalopram. Sedation is more common.
The pregnancy story is the most consequential. Paroxetine is FDA pregnancy category D — observational studies have linked first-trimester paroxetine exposure to a small but consistent increase in cardiac malformations, particularly atrial and ventricular septal defects. The absolute risk increase is modest; the relative risk signal is real. The standard of care today is to avoid initiating paroxetine in women of childbearing potential when alternatives exist, and to switch existing paroxetine patients to sertraline before planned pregnancy.
Despite all this, paroxetine has not disappeared from clinical practice, and there are specific situations where it remains the right choice. Paroxetine is FDA-approved for PTSD, where the evidence base is solid. It has specific evidence for severe social anxiety disorder that some clinicians weigh heavily. Patients who have responded well to paroxetine historically without intolerable side effects often stay on it.
The general lesson: not every SSRI is interchangeable. The patient choosing paroxetine today should be doing so deliberately, with eyes open to what the drug brings — and not by default because someone forgot to think about which SSRI fit best. Anticholinergic burden, severe discontinuation, sexual dysfunction prominence, and pregnancy avoidance are the four facts you carry forward.